Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

From Bettina Bauer, Vice President, US HIV Treatment and Prevention, Gilead Sciences In 2022, there were up to 1.2 million ...

Tremendous successes have been achieved in treating and caring for people living with HIV and in developing HIV prevention technologies such as pre-exposure prophylaxis (PrEP) and post-exposure ...

Once regarded as a crisis, Kenya has made significant strides in combating the disease, reducing new infections by 53 per ...

The federal government yesterday formally announced the commencement of the HIV Vaccine Innovation, Science, and Technology ...

Early symptoms of mono and acute HIV infection include body aches, fatigue, fever, headaches, sore throat, and swollen lymph ...

Revolutionary new HIV drugs are being made available in 120 low-income countries, but many important populations are being left out. Sophie Cousins reports.

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...

The global western blotting market is on a steady growth trajectory, with market valuation expected to rise from USD 980.1 million in 2023 to USD 1,753.4 million by 2033, marking a robust CAGR of 6% ...

The inalienable right of every Nigerian to equitable access to quality healthcare cannot be overstated. A firm believer in ...